ProxyMiner / Company

NovoCure LtdNVCR

Latest proxy: 2026 · view on SEC ↗ · CIK 0001645113

CEO total pay

$6,975,329

Frank Leonard · 2025

Say on pay

Not disclosed

Use Ask for the underlying narrative

CEO pay ratio

Item 402(u)

84 to 1

Median employee: $148,799

Compensation committee

CD&A

Compensation Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
Ashley Cordova2025 compensation
Former Chief Executive Officer
$13,198,354↑ 117%
90% at-risk
$901,837$8,249,965$811,653$482,085
Frank Leonard2025 compensation
Chief Executive Officer
$6,975,329
92% at-risk
$570,000$4,999,993$389,644$14,672
Christoph Brackmann2025 compensation
Chief Financial Officer
$4,163,398
80% at-risk
$541,102$1,999,991$324,661$296,624
Uri Weinberg2025 compensation
Chief Medical and Innovation Officer
$4,159,945↓ 18%
79% at-risk
$541,102$1,999,991$270,551$347,281
Nicholas Leupin2025 compensation
Former Chief Medical Officer
$3,999,041
82% at-risk
$553,151$1,999,991$276,575$168,304
Michael Puri2025 compensation
Chief Human Resources Officer
$3,933,893
83% at-risk
$511,089$1,999,991$255,545$166,248

Pay mix: base cash incentive equity other

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

Executive Summary This section discusses and analyzes the decisions we made concerning the compensation of our NEOs for 2025. It also describes the process for determining executive compensation and the factors considered in determining the amount of compensation awarded to our NEOs. Mr. Danziger, our Chief Executive Officer, and Mr. Doyle, our Executive Chairman, have been critical to Novocure’s success and have collaborated for nearly 20 years to advance our therapy from the preclinical stage through clinical studies to regulatory approvals and ultimately to commercial sales in the United States, Europe, Japan, and Greater China. They have recruited, engaged, and retained an exceptional senior leadership team. Because we know of no precedent for our business model and cancer therapy, we believe it is vital to our current and future success, and to the continued creation of value for our shareholders, that we retain our experienced leadership team with a proven track record of innovation and success. Our NEOs for 2025 are: NameTitleFrank LeonardChief Executive Officer (1)Ashley CordovaChief Executive Officer and director (2)Christoph BrackmannChief Financial OfficerNicolas LeupinC…

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • compensation consultant

    independent

    “independent compensation consultant monitored our performance and did not make any significant changes to our compensation philosophy”

  • compensation committee

    Compensation Committee

    “Our Compensation Committee believes that the PSUs awarded to Mr”

  • hedging

    COMPENSATION DISCUSSION AND ANALYSIS Executive Summary This section discusses and analyzes the decisions we made concerning the compensation of our NEOs for 2025. It also describes the process for determining executive compensation and the factors considered in determining the am

    “COMPENSATION DISCUSSION AND ANALYSIS Executive Summary This section discusses and analyzes the decisions we made concerning the compensation of our NEOs for 2025. It also describes the process for determining executive c…”

  • pledging

    COMPENSATION DISCUSSION AND ANALYSIS Executive Summary This section discusses and analyzes the decisions we made concerning the compensation of our NEOs for 2025. It also describes the process for determining executive compensation and the factors considered in determining the am

    “COMPENSATION DISCUSSION AND ANALYSIS Executive Summary This section discusses and analyzes the decisions we made concerning the compensation of our NEOs for 2025. It also describes the process for determining executive c…”

  • clawback

    present

    “Recoupment Policy and other internal business and operational approval processes.”

  • stock ownership guidelines

    present

    “Share Ownership Guidelines”

  • change in control

    COMPENSATION DISCUSSION AND ANALYSIS Executive Summary This section discusses and analyzes the decisions we made concerning the compensation of our NEOs for 2025. It also describes the process for determining executive compensation and the factors considered in determining the am

    “COMPENSATION DISCUSSION AND ANALYSIS Executive Summary This section discusses and analyzes the decisions we made concerning the compensation of our NEOs for 2025. It also describes the process for determining executive c…”

Performance markers

Metric facts

  • revenue

    $951.5 million

    “patients, and (4) at least one Substantial Innovation has passed through stage gate "Exit 2" as of December 31, 2027 pursuant to the Stage Gate Process. A number of outperformance 2025 PSUs are eligible to be earned on t…”

  • time equity mix

    50%

    “The Committee granted our NEOs time-based RSU awards to support our compensation philosophy, provide significant performance incentives and create retention value, as presented in the 2025 Grants of Plan-Based Awards Tab…”

  • ceo pay ratio

    84 to 1

    “November 30, 2025. We have estimated the median of the 2025 annual total compensation of our employees, excluding our CEO, to be $148,799. The 2025 annualized total compensation of Ms. Cordova as reported in the Summary …”

  • median employee compensation

    $148,799

    “of our employees outside the U.S. were converted to U.S. dollars using the currency exchange rates used for organizational planning purposes. We did not make any cost of living adjustments. For purposes of this disclosur…”

Ask

Anything about NovoCure Ltd’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…